Capricor Sues Distributor Over 'Fundamental Pricing Flaw' Threatening Deramiocel US Launch
CAPR has more than doubled off its 52-week low of $4.3.
Summary
Capricor Therapeutics has filed a lawsuit against its U.S. distributor, NS Pharma/Nippon Shinyaku, seeking rescission of their distribution agreement and an injunction to protect the upcoming U.S. launch of its key drug, Deramiocel. The company alleges a material breach of contract, citing a "fundamental pricing flaw" that renders commercialization economically unviable for major payors, and a failure by the distributor to prepare for the launch. This legal action is critical as Deramiocel, which received positive Phase 3 results and FDA Priority Review with an August 22, 2026 PDUFA date, is central to Capricor's future revenue. The lawsuit introduces significant uncertainty and potential delays to the commercialization of a flagship product, which could materially impact the company's financial outlook. Investors should monitor the legal proceedings and any updates on the Deramiocel launch timeline.
At the time of this announcement, CAPR was trading at $33.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $4.30 to $40.37. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.